

Claim 27. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist ligand subcutaneously.

Claim 28. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT₄ receptor antagonist ligand orally.

REMARKS

1. Election Restriction:

In response to the restriction based on 35 U.S.C. § 121, the Applicants state:

Group II Claims 8-28 are elected for prosecution and Group I Claims 1-7 are reserved for the option of filing a divisional at a later date.

2. Specification Objections:

In response to the rejection of Claims 8-28 under 35 U.S.C. § 1.821-1.825 and 35 U.S.C. § 112 as failing to comply with the written description requirement supporting claims for a genus of molecules the specification has been amended to include only the three putative antagonists (named by abbreviation in Figure 6B) that were demonstrated in Figure 6B to exhibit anti-angiogenic activity. No new matter has been added to this specification. SEQ ID Nos. are included on Pages 7 and 8 of this response and a disk of the listing is enclosed.

3. Claim rejections:

Reconsideration and removal of the rejection of the claims 8-28 based on 35 U.S.C. § 102 (e) as being anticipated by WO 03/011304A1 (Albiston et al., October 17, 2001) is rendered moot on the amendment of claims to include only the three putative antagonists demonstrated to be efficacious in Figure 6B.


Reconsideration and removal of the rejection of the claims 8-28 for obviousness based on 35 U.S.C. § 103(a) as being unpatentable over Masino, J. ("Identification of the Angiotensin IV Receptor Antagonist, Norleual, as a Novel Inhibitor of

Angiogenesis and Tumor Growth", Dissertation Abstracts International, May 2003, Vol.64, No. 7B) and based on 35 U.S.C. § 102(a) is obviated in view of the attached KATZ declaration indicating that the technology described by Masino was developed while working under the direction of Drs. Joseph W. Harding and John W. Wright, who are the sole inventors of the described technology.

Applicants respectfully request a timely Notice of Allowance be issued in this case.

Respectfully submitted,

Northwest Patent Law

By 

John Hughes

Reg. No. 47,236 Tel. (509)332-4995